A detailed history of Bailard, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Bailard, Inc. holds 11,193 shares of LLY stock, worth $8.35 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
11,193
Previous 13,097 14.54%
Holding current value
$8.35 Million
Previous $11.9 Million 16.37%
% of portfolio
0.26%
Previous 0.33%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$772.14 - $960.02 $1.47 Million - $1.83 Million
-1,904 Reduced 14.54%
11,193 $9.92 Million
Q2 2024

Jul 25, 2024

BUY
$724.87 - $909.04 $395,779 - $496,335
546 Added 4.35%
13,097 $11.9 Million
Q1 2024

May 08, 2024

SELL
$592.2 - $792.28 $258,199 - $345,434
-436 Reduced 3.36%
12,551 $9.76 Million
Q4 2023

Feb 02, 2024

BUY
$525.19 - $619.13 $302,509 - $356,618
576 Added 4.64%
12,987 $7.57 Million
Q3 2023

Oct 24, 2023

SELL
$434.7 - $599.3 $752,465 - $1.04 Million
-1,731 Reduced 12.24%
12,411 $6.67 Million
Q2 2023

Jul 20, 2023

BUY
$350.74 - $468.98 $1.33 Million - $1.78 Million
3,801 Added 36.76%
14,142 $6.63 Million
Q1 2023

May 08, 2023

SELL
$310.63 - $364.82 $41,624 - $48,885
-134 Reduced 1.28%
10,341 $3.55 Million
Q4 2022

Feb 02, 2023

SELL
$321.55 - $374.67 $33,762 - $39,340
-105 Reduced 0.99%
10,475 $3.83 Million
Q3 2022

Oct 18, 2022

BUY
$296.48 - $337.87 $185,892 - $211,844
627 Added 6.3%
10,580 $3.42 Million
Q2 2022

Jul 27, 2022

BUY
$278.73 - $327.27 $645,259 - $757,630
2,315 Added 30.31%
9,953 $3.23 Million
Q1 2022

Apr 25, 2022

SELL
$234.69 - $291.66 $221,782 - $275,618
-945 Reduced 11.01%
7,638 $2.19 Million
Q4 2021

Feb 10, 2022

SELL
$224.85 - $279.04 $3,372 - $4,185
-15 Reduced 0.17%
8,583 $2.37 Million
Q3 2021

Nov 15, 2021

BUY
$221.6 - $272.71 $89,526 - $110,174
404 Added 4.93%
8,598 $1.99 Million
Q2 2021

Aug 13, 2021

BUY
$180.55 - $233.54 $32,679 - $42,270
181 Added 2.26%
8,194 $1.88 Million
Q1 2021

May 13, 2021

BUY
$164.32 - $212.72 $345,564 - $447,350
2,103 Added 35.58%
8,013 $1.5 Million
Q4 2020

Feb 03, 2021

SELL
$130.46 - $172.63 $88,712 - $117,388
-680 Reduced 10.32%
5,910 $998,000
Q3 2020

Nov 10, 2020

BUY
$146.22 - $169.13 $42,111 - $48,709
288 Added 4.57%
6,590 $975,000
Q2 2020

Aug 12, 2020

BUY
$136.42 - $164.18 $457,961 - $551,152
3,357 Added 113.99%
6,302 $1.04 Million
Q1 2020

Apr 16, 2020

SELL
$119.05 - $147.35 $2,381 - $2,947
-20 Reduced 0.67%
2,945 $409,000
Q4 2019

Jan 31, 2020

SELL
$106.92 - $132.43 $4,490 - $5,562
-42 Reduced 1.4%
2,965 $390,000
Q3 2019

Oct 18, 2019

SELL
$106.79 - $116.16 $32,037 - $34,848
-300 Reduced 9.07%
3,007 $336,000
Q2 2019

Jul 26, 2019

BUY
$110.79 - $129.32 $56,281 - $65,694
508 Added 18.15%
3,307 $366,000
Q1 2019

Apr 24, 2019

BUY
$111.31 - $131.02 $14,136 - $16,639
127 Added 4.75%
2,799 $363,000
Q4 2018

Feb 05, 2019

BUY
$105.9 - $118.64 $9,742 - $10,914
92 Added 3.57%
2,672 $309,000
Q3 2018

Nov 13, 2018

BUY
$85.86 - $107.31 $221,518 - $276,859
2,580 New
2,580 $277,000
Q1 2018

May 07, 2018

SELL
$74.21 - $87.6 $202,741 - $239,323
-2,732 Closed
0 $0
Q4 2017

Feb 08, 2018

BUY
$81.94 - $87.89 $25,401 - $27,245
310 Added 12.8%
2,732 $0
Q1 2017

Jan 29, 2018

BUY
N/A
2,422
2,422 $204,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $709B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Bailard, Inc. Portfolio

Follow Bailard, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.